CA
CRL icon

Crewe Advisors’s Charles River Laboratories CRL Stock Holding History

Crewe Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-48
Closed -$9.92K – 774
2024
Q2 		$9.92K Buy
+48
New +$10.9K ﹤0.01% 695
2022
Q4 		– Sell
-28
Closed -$6K – 1075
2022
Q3 		$6K Hold
28
– – ﹤0.01% 789
2022
Q2 		$6K Buy
+28
New +$6.84K ﹤0.01% 715

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Crewe Advisors's CRL Position: Q3 2024 in Review

Crewe Advisors sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 48 shares — an estimated $9.92K sold.

Crewe Advisors first reported a position in CRL in Q2 2022 and held it in 3 quarters. The position peaked at $9.92K in Q2 2024. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Crewe Advisors reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Crewe Advisors sold 48 Charles River Laboratories shares in Q3 2024, an estimated $9.92K.
  • Crewe Advisors first reported a position in Charles River Laboratories in Q2 2022 and held it in 3 quarters.
  • Crewe Advisors's Charles River Laboratories position peaked at $9.92K in Q2 2024.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Crewe Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.